Agilent Expands Cell Analysis Portfolio with Acquisition of Luxcel Biosciences
Image credit: Luxcel Biosciences
Agilent Technologies Inc. announced it has acquired Cork, Ireland-based Luxcel Biosciences (“Luxcel”), a developer of real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands Agilent’s cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.
“Technological advancements allowing researchers to examine cell health and function kinetically and in real-time are driving global demand for complete cell analysis solutions,” said Todd Christian, General Manager of Agilent’s Cell Analysis Division. “Luxcel’s assay kits are optimized for standard fluorescent plate readers for broad customer application helping to address this growing demand.”
Luxcel is developing a portfolio of in vitro cell-based assay kits and solutions targeting cell metabolism, drug safety and toxicity, as well as hypoxia and oxidative stress for a variety of life science customers from research institutions to pharmaceutical companies. Scientists use this technology to understand the roll of cell metabolism across a variety of important research areas including cancer, metabolic disorders, cardiovascular disease, immunology, and infectious disease.
Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in providing specialized instruments and live-cell, kinetic assays. “Luxcel is highly complementary to our Seahorse offerings,” said Christian. “With this acquisition, we further extend our leadership in live-cell, kinetic assays accelerating our expansion into pharmaceutical and biopharma discovery and in vitro toxicology screening applications.”
“We are a young and motivated group,” said Richard Fernandes, CEO of Luxcel. “When Agilent approached us, it was clear to me that we have a shared passion for innovation designed to enable and support customers. Together, we have the potential to accelerate new product introductions by leveraging Agilent’s R&D and global commercial infrastructures with our unique biosensor chemistries and assay development expertise.”
Computational Model Underlines Need for Personalised Approach to SepsisNews
A computational model of the human immune system has enabled researchers to explore the challenges of tackling sepsis.READ MORE
Drug Transport Gene May Explain Why Ovarian Cancer Patients React Differently to ChemotherapyNews
A gene which produces a protein that transports drugs in and out of cells may explain why some women treated with chemo have serious side effects.READ MORE
Comments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.Analysis & Separations Applied Sciences Cancer Research Cell Science Drug Discovery Proteomics & Metabolomics Immunology & Microbiology
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE